Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049575 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
A Phase 1 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT07049575 is a Phase 1 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 24 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07049575, a Phase 1 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
Study Locations (20)
California
- First Oc Dermatology - Fountain Valley
- Amicis Research Center Valencia - Northridge
- Children'S Hospital of Orange County - Orange
- Clinical Trials Research Institute - Thousand Oaks
Florida
- Advanced Pharma Cr, Llc - Miami
- International Clinical Research Tennessee Llc - Sanford
- Lenus Research Medical Group, Llc - Sweetwater
- Trueblue Clinical Research - Tampa
New York
- Dr Bobby Buka, Md Greenwich Village - New York
- Equity Medical, Llc - New York
Arizona
- Saguaro Dermatology - Phoenix
Colorado
- Clarity Dermatology - Castle Rock
Georgia
- Lane Dermatology and Dermatologic Surgery - Columbus
Indiana
- Options Research Group, Llc - West Lafayette
Kentucky
- Equity Medical, Llc - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07049575
The ClinicalTrials.gov registry entry for NCT07049575 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (96% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Cream is the first listed.
NCT07049575 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07049575 about?
NCT07049575 is a clinical study titled "Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa". The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
What is the current status of trial NCT07049575?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-11-03. Estimated completion is 2026-12-09.
What conditions does trial NCT07049575 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT07049575?
The interventions under investigation include: Ruxolitinib Cream (DRUG).
Who is sponsoring clinical trial NCT07049575?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049575 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
ACTIVE NOT RECRUITING · Phase 1
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.